Kyowa Kirin News Releases
https://www.kyowakirin.com/media_center/news_releases/index.html
Kyowa Kirin News ReleasesenKyowa Kirin Co., Ltd.Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-fda-approval-lenmeldytm
2024-03-19T13:00+09:00Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240311_01.pdf
2024-03-11T17:30+09:00Kyowa Kirin Announces Launch of PHOZEVEL® Tablets for Improvement of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis in Japan
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240219_01.pdf
2024-02-19T16:00+09:00Announcement of Consolidated Financial Results Fiscal 2023
https://ir.kyowakirin.com/en/library/earnings.html#23q4
2024-02-07T15:40+09:00Notice regarding Acquisition of Own Shares and Cancellation of Treasury Shares
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240207_02.pdf
2024-02-07T15:40+09:00BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240207_01.pdf
2024-02-07T15:40+09:00Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240206_01.pdf
2024-02-06T21:00+09:00Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-first-patient-randomized
2024-02-06T16:00+09:00Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc (overview of the acquisition)
https://data.swcms.net/file/kyowakirin/en/news/auto_20240125518893/pdfFile.pdf
2024-01-25T16:10+09:00Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240124_02.pdf
2024-01-24T19:00+09:00Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240124_01.pdf
2024-01-24T19:00+09:00Boehringer Ingelheim licenses a new compound as part of its commitment to people living with fibro-inflammatory diseases from Kyowa Kirin
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240105_01.pdf
2024-01-05T16:00+09:00